CAMBRIDGE, England and WALTHAM, Mass., Nov. 11,
2022 /PRNewswire/ -- Abcam plc (AIM: ABCM) (ABC:
ABCM) (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in
the supply of life science research tools, today announces that the
resolution put to its General Meeting held today for the
cancellation of the admission of its Ordinary Shares to trading on
AIM was passed.
The votes were as follows:
Special
Resolution
|
|
In
Favour
|
% In
Favour
|
Against
|
%
Against
|
% of ISC
voted
|
Withheld
|
1.
|
Approve the
cancellation
of the admission to trading
on AIM of the ordinary
shares of nominal value
0.2p each in the capital of
the Company and
authorise the directors of
the Company to take all
action reasonable or
necessary to effect such
cancellation
|
|
189,580,480
|
98.19 %
|
3,485,254
|
1.81 %
|
84.29 %
|
60,213
|
|
|
|
|
|
|
|
|
|
The issued share capital ("ISC") as of the date of the meeting
was 229,059,401 Ordinary Shares.
The percentage of voting shares in favour and against is the
percentage of shares voted and exclude shares on which votes were
withheld.
The Company will continue to provide shareholders with an
opportunity to deposit their Ordinary Shares with the Depositary in
exchange for delivery of ADSs, without cost, in connection with the
AIM Delisting prior to or on 14 December
2022 (being the date on which the AIM Delisting takes
effect). Further details are set out in the Shareholder Circular
dated 17 October 2022, available at
https://corporate.abcam.com/investors/aim-delisting/.
The Company confirms that, as at today's date, the pending
timetable for the cancellation of the admission to trading on AIM
of the Company's ordinary shares is as follows:
PENDING TIMETABLE
Last date for receipt
by the Registrar from
certificated shareholders of duly completed
Certificated Transfer Forms and original share
certificates
|
5.00 p.m. on 1 December
2022
|
Latest date for receipt
by the Depositary from
CREST holders of duly completed issuance forms
|
5.00 p.m. on 1 December
2022
|
Expected date for
issuance of ADSs to block
transfer participants
|
12 December
2022
|
Expected date of
mailing of ADS confirmations to
shareholders by the Depositary
|
13 December
2022
|
Last day of dealings in
the Ordinary Shares on AIM
|
13 December
2022
|
Cancellation of
admission to trading on AIM of the
Ordinary Shares
|
7.00 a.m. on 14
December 2022
|
_______
Notes to the
timetable
(1) References to times and dates
in this announcement are to times and dates in London, United Kingdom, unless otherwise
stated.
(2) Each of the times and dates in the above timetable are
subject to change. If any of the above times and/or dates change,
the revised times and/or dates will be notified to shareholders by
announcement through a Regulatory Information Service.
The capitalised terms used in this announcement have the meaning
set out in the announcement made by the Company at 7.00 a.m.
on 17 October 2022.
For further information, please contact:
Abcam
|
+ 44 (0) 1223 696
000
|
Marc Perkins, Company
Secretary
Tommy J. Thomas, CPA,
Vice President, Investor Relations
|
+1 617 577
4205
|
Numis – Nominated
Advisor & Joint Corporate Broker
|
+ 44 (0) 20 7260
1000
|
Freddie Barnfield /
Duncan Monteith
|
|
Morgan Stanley –
Joint Corporate Broker
|
+ 44 (0) 207 425
8000
|
Tom Perry / Luka
Kezic
|
|
FTI
Consulting
|
+ 44 (0) 20 3727
1000
|
Ben Atwell / Lydia
Jenkins / Julia Bradshaw
|
|
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent program of customer reviews and
datasheets, combined with industry-leading validation initiatives,
gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served
customers in more than 130 countries. Abcam's ordinary shares are
listed on the London Stock Exchange (AIM: ABC) and its American
Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq:
ABCM).
For more information, please visit www.abcam.com or
www.abcamplc.com.
Forward-Looking Statements
This announcement contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Any express or implied statements contained in this
announcement that are not statements of historical fact may be
deemed to be forward-looking statements, including, without
limitation, statements regarding Abcam's portfolio and ambitions,
expectations surrounding the timing of the AIM Delisting, as well
as statements that include the words "expect," "intend," "plan,"
"believe," "project," "forecast," "estimate," "may," "should,"
"anticipate" and similar statements of a future or forward-looking
nature. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the
important factors discussed under the caption "Risk Factors" in
Abcam's Annual Report on Form 20-F for the year ended 31 December 2021, which is on file with the SEC
and is available on the SEC website at www.sec.gov, as such factors
may be updated from time to time in Abcam's other filings with the
SEC. Any forward-looking statements contained in this
announcement speak only as of the date hereof and accordingly
undue reliance should not be placed on such statements. Abcam
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this
announcement, whether as a result of new information, future
events or otherwise, other than to the extent required by
applicable law.
Logo -
https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg
Contact:
Tommy Thomas
tommy.thomas@abcam.com
View original
content:https://www.prnewswire.com/news-releases/abcam-plc-result-of-general-meeting--shareholders-approve-aim-delisting-301675699.html
SOURCE Abcam plc